WEBINAR SERIES

  1. Home
  2. Webinars
  3. March 2023

ISLH Webinar:"Diagnostic Flow Cytometry: Case-Based Problem Solving" as presented at the 2022 WASPaLM Meeting, Punta del Este, Uruguay, October 1, 2022

Speakers

Nydia Strachman Bacal, MD, MBA
Ruth Padmore, MD, FRCPC, PhD
Daniela Lens, MD, PhD
Alex Freire Sandes, MD, PhD

""Diagnostic Flow Cytometry: Case-Based Problem Solving" as presented at the 2022 WASPaLM Meeting, Punta del Este, Uruguay, October 1, 2022"

Learning Objectives:

  • Demonstrate efficient solutions, with lowest cost and quality that can minimize the pre-analytical and analytical work in the flow cytometry sector with the use of the tube with dry reagents and analysis by the radar methodology.

  • Using a case-based approach, to know the flow immunophenotyping patterns of benign and neoplastic immature B-cells in the marrow, in patients with no previous treatment.

  • Introducing the utility of T-cell Receptor Constant β Chain-1 (TRBC1) flow cytometric assay for the diagnostic work-up of T-cell malignancies.

  • NPM1 mutation and its prevalence in de novo AML cases.

  • Diagnostic methods available for AML and how they can be used to detect NPM1 mutations

  • Learning about the APL-like phenotype and the monocytic maturation pattern with CD300/CD14 inversion, which are highly predictive of the NPM1 mutation





    • Watch the Webinar





    Answers to Questions from Live Webinar

    Below is a list of questions received from the live webinar attendees. Click on any question to reveal the speaker's response.

    NEW QUESTION/ANSWER

    It is common to see necrosis in cHL, hard to put a number on it offhand.

    NEW QUESTION/ANSWER

    Classic in the 2017 WHO

    NEW QUESTION/ANSWER

    It can be expressed in both CHL and ALCL so it may not be reliable.

    NEW QUESTION/ANSWER

    CD15, CD30, CD20, PAX5, OCT2, BOB1 and CD45 can be helpful.

    NEW QUESTION/ANSWER

    I have never seen this.

    NEW QUESTION/ANSWER

    No, there is no clinical role for this at present.

    NEW QUESTION/ANSWER

    This would be highly unusual

    NEW QUESTION/ANSWER

    I don’t have any experience with J chain but is usually negative in RS-cells. MUM1 is typically positive but not specific.

    NEW QUESTION/ANSWER

    No

    NEW QUESTION/ANSWER

    Yes. J-chain and MEF2B have been reported to be useful as well. PMID: 28851661

    NEW QUESTION/ANSWER

    I don’t think it is particularly helpful, some cases of cHL may have rearranged IGH

    NEW QUESTION/ANSWER

    No

    NEW QUESTION/ANSWER

    I don’t find it that helpful

    NEW QUESTION/ANSWER

    There has been some data to suggest it is prognostic.

    NEW QUESTION/ANSWER

    It does not appear to commonly result in loss of CD30 expression in follow-up biopsy but I don’t believe this has been extensively studied.

    NEW QUESTION/ANSWER

    Yes, for T-cell lymphomas including cutaneous T-cell lymphomas it is reasonable to report the % positive tumor cells because some trials that resulted in the approval of brentuximab used specific cutoffs.